Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/180605
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFarrera Sal, Martí-
dc.contributor.authorMoreno, Rafael-
dc.contributor.authorMato Berciano, Ana-
dc.contributor.authorMaliandi, María Victoria-
dc.contributor.authorBazan Peregrino, Miriam-
dc.contributor.authorAlemany, Ramon-
dc.date.accessioned2021-10-18T07:03:26Z-
dc.date.available2021-10-18T07:03:26Z-
dc.date.issued2021-09-01-
dc.identifier.issn2372-7705-
dc.identifier.urihttp://hdl.handle.net/2445/180605-
dc.description.abstractOncolytic viruses (OVs) preferentially infect and selectively replicate in cancer cells. OVs have been tested in clinical trials as monotherapy or in combination with chemotherapy, radiotherapy, and immunotherapy. However, the dense extracellular matrix hampers the intratumoral spreading and efficacy of OVs. Previously we described VCN-01, an oncolytic adenovirus expressing a soluble version of human sperm hyaluronidase (hyal) PH20, which exhibited enhanced intratumoral distribution and antitumor activity in different models. Here, we present two oncolytic adenoviruses designed to increase the secretion of PH20 compared to VCN-01. ICO15K-40SAPH20, encoding PH20 under an Ad40 splice acceptor, and ICO15K-E1aPH20 expressing PH20 fused to the E1A gene by P2A peptide. We demonstrate that increased hyal activity improves antitumor efficacy in both a sensitive immunodeficient model and an immunocompetent model. Moreover, we show that hyal activity impacts T cell accumulation in tumors, highlighting the value of a hyaluronidase-expressing virus for combinations with other immunotherapies in cancers involving dense stroma.-
dc.format.extent17 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier BV-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.omto.2021.05.009-
dc.relation.ispartofMolecular Therapy - Oncolytics, 2021, vol. 22, p. 27-35-
dc.relation.urihttps://doi.org/10.1016/j.omto.2021.05.009-
dc.rightscc by (c) Farrera Sal, Martí et al, 2021-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subject.classificationVirus-
dc.subject.classificationCàncer-
dc.subject.classificationTerapèutica-
dc.subject.otherViruses-
dc.subject.otherCancer-
dc.subject.otherTherapeutics-
dc.titleHyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2021-10-14T09:17:34Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid34377767-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
PIIS2372770521000759.pdf2.28 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons